Table 3. Open in new tab Predicted...

		Cefepime breakpoints (mg/L) (i.e. the highest MIC at which ≥90% of the participants achieve targets)
2 g q8h 30 min infusion	All	8	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	4	8
1 g q8h 30 min infusion	All	4	8
	<60 mL/min	16	16
	60–129 mL/min	4	8
	≥130 mL/min	1	4
2 g q12h 30 min infusion	All	2	8
	<60 mL/min	16	32
	60–129 mL/min	4	8
	≥130 mL/min	1	4
1 g q12h 30 min infusion	All	1	4
	<60 mL/min	8	16
	60–129 mL/min	2	4
	≥130 mL/min	0.5	2
2 g q8h 3 h infusion	All	8	16
	<60 mL/min	32	64
	60–129 mL/min	16	32
	≥130 mL/min	4	16
1 g q8h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	8	16
	≥130 mL/min	2	8
2 g q12h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	4	16
	≥130 mL/min	1	4
1 g q12h 3 h infusion	All	2	4
	<60 mL/min	8	16
	60–129 mL/min	2	8
	≥130 mL/min	0.5	2
3 g q24h 24 h infusion	All	16	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	8	8
6 g q24h 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	16	16
8 g q24 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	32	32

Cefepime breakpoints (mg/L)
(i.e. the highest MIC at which ≥90% of the participants achieve targets)

Dosing regimen^a

CLCR

Target 100% fT > MIC

Target 65% fT > MIC

2 g q8h 30 min infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

1 g q8h 30 min infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

2 g q12h 30 min infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

1 g q12h 30 min infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

0.5

2 g q8h 3 h infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

1 g q8h 3 h infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

2 g q12h 3 h infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

1 g q12h 3 h infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

0.5

3 g q24h 24 h infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

6 g q24h 24 h infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

8 g q24 24 h infusion

All

<60 mL/min

60–129 mL/min

≥130 mL/min

		Cefepime breakpoints (mg/L) (i.e. the highest MIC at which ≥90% of the participants achieve targets)
2 g q8h 30 min infusion	All	8	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	4	8
1 g q8h 30 min infusion	All	4	8
	<60 mL/min	16	16
	60–129 mL/min	4	8
	≥130 mL/min	1	4
2 g q12h 30 min infusion	All	2	8
	<60 mL/min	16	32
	60–129 mL/min	4	8
	≥130 mL/min	1	4
1 g q12h 30 min infusion	All	1	4
	<60 mL/min	8	16
	60–129 mL/min	2	4
	≥130 mL/min	0.5	2
2 g q8h 3 h infusion	All	8	16
	<60 mL/min	32	64
	60–129 mL/min	16	32
	≥130 mL/min	4	16
1 g q8h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	8	16
	≥130 mL/min	2	8
2 g q12h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	4	16
	≥130 mL/min	1	4
1 g q12h 3 h infusion	All	2	4
	<60 mL/min	8	16
	60–129 mL/min	2	8
	≥130 mL/min	0.5	2
3 g q24h 24 h infusion	All	16	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	8	8
6 g q24h 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	16	16
8 g q24 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	32	32

Table 3.

Open in new tab

Predicted cefepime breakpoints following different dose regimens in all subjects as well as subjects with different renal functions

		Cefepime breakpoints (mg/L) (i.e. the highest MIC at which ≥90% of the participants achieve targets)
Dosing regimen^a	CLCR	Target 100% fT > MIC	Target 65% fT > MIC
2 g q8h 30 min infusion	All	8	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	4	8
1 g q8h 30 min infusion	All	4	8
	<60 mL/min	16	16
	60–129 mL/min	4	8
	≥130 mL/min	1	4
2 g q12h 30 min infusion	All	2	8
	<60 mL/min	16	32
	60–129 mL/min	4	8
	≥130 mL/min	1	4
1 g q12h 30 min infusion	All	1	4
	<60 mL/min	8	16
	60–129 mL/min	2	4
	≥130 mL/min	0.5	2
2 g q8h 3 h infusion	All	8	16
	<60 mL/min	32	64
	60–129 mL/min	16	32
	≥130 mL/min	4	16
1 g q8h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	8	16
	≥130 mL/min	2	8
2 g q12h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	4	16
	≥130 mL/min	1	4
1 g q12h 3 h infusion	All	2	4
	<60 mL/min	8	16
	60–129 mL/min	2	8
	≥130 mL/min	0.5	2
3 g q24h 24 h infusion	All	16	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	8	8
6 g q24h 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	16	16
8 g q24 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	32	32

		Cefepime breakpoints (mg/L) (i.e. the highest MIC at which ≥90% of the participants achieve targets)
Dosing regimen^a	CLCR	Target 100% fT > MIC	Target 65% fT > MIC
2 g q8h 30 min infusion	All	8	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	4	8
1 g q8h 30 min infusion	All	4	8
	<60 mL/min	16	16
	60–129 mL/min	4	8
	≥130 mL/min	1	4
2 g q12h 30 min infusion	All	2	8
	<60 mL/min	16	32
	60–129 mL/min	4	8
	≥130 mL/min	1	4
1 g q12h 30 min infusion	All	1	4
	<60 mL/min	8	16
	60–129 mL/min	2	4
	≥130 mL/min	0.5	2
2 g q8h 3 h infusion	All	8	16
	<60 mL/min	32	64
	60–129 mL/min	16	32
	≥130 mL/min	4	16
1 g q8h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	8	16
	≥130 mL/min	2	8
2 g q12h 3 h infusion	All	4	8
	<60 mL/min	16	32
	60–129 mL/min	4	16
	≥130 mL/min	1	4
1 g q12h 3 h infusion	All	2	4
	<60 mL/min	8	16
	60–129 mL/min	2	8
	≥130 mL/min	0.5	2
3 g q24h 24 h infusion	All	16	16
	<60 mL/min	32	32
	60–129 mL/min	16	16
	≥130 mL/min	8	8
6 g q24h 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	16	16
8 g q24 24 h infusion	All	32	32
	<60 mL/min	64	64
	60–129 mL/min	32	32
	≥130 mL/min	32	32

For each dosing regimen, 6500 virtual subjects were simulated, including 2100 subjects with CL_CR <60 mL/min, 2850 subjects with CL_CR between 60 and 129 mL/min, and 1550 subjects with CL_CR >130 mL/min.

This Feature Is Available To Subscribers Only